Ropes & Gray Represents Sanofi in Investment in Atalanta Therapeutics’ $97 Million Series B Financing

In The News
January 31, 2025

Ropes & Gray represented Sanofi in its role as co-lead investor in Atalanta Therapeutics’ $97 million Series B financing. Atalanta is a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases.

The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from other new investors RiverVest Venture Partners, funds managed by abrdn Inc, Novartis Venture Fund, Pictet Alternative Advisors, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital.

The Ropes & Gray team included venture capital and emerging companies associates Daniel Freshman and Derek Mubiru, venture capital and emerging companies partner Rajarshi Banerjee, and litigation & enforcement partner Brendan Hanifin.